Buy Tremfya (guselkumab)

What is Tremfya (guselkumab) for?

Buy Tremfya (guselkumab). Tremfya (guselkumab) is a treatment for adults with:

• Moderate-to-severe plaque psoriasis who need systemic therapy or light therapy.
• Active psoriatic arthritis (PsA).

It comes in a single-dose syringe with 100 mg guselkumab.

How does Tremfya (guselkumab) work?

Psoriasis is a chronic autoimmune condition. It causes raised, inflamed skin. Psoriatic arthritis is a chronic inflammatory arthritis that affects joints and connective tissue.

Interleukin 23 (IL-23) is key in psoriasis development. Cytokines are proteins that signal in cells. IL-23 signaling can lead to inflammation, causing psoriasis.

Guselkumab is a human monoclonal antibody. It binds to IL-23, blocking its action. This slows down inflammation in patients.

Where has Tremfya (guselkumab) been approved?

Tremfya (guselkumab) has been approved by:

• The Food and Drug Administration (FDA), US:
  • July 13, 2017 for treating adult patients with moderate to severe plaque psoriasis.
  • July 14, 2020 for treating adult patients with active PsA.
• The European Medicines Agency (EMA), Europe:
  • November 10, 2017 for treating adults with moderate to severe psoriasis.
• Health Canada, Canada:
  • November 15, 2017 for treating adults with moderate to severe plaque psoriasis.
• The Pharmaceuticals and Medical Devices Agency (PMDA), Japan:
  • April 7, 2018 for treating three types of psoriasis (plaque, pustular, and erythrodermic) and PsA in patients with moderate-to-severe disease.
• The Therapeutic Goods Administration (TGA), Australia:

• February 1, 2019 for treating severe chronic plaque psoriasis.

Tremfya (guselkumab) is the first and only approved medication that selectively blocks only IL-23.

This medicine may also be approved in other regions. If you have a question about its approval in a specific country, feel free to contact our support team.

How is Tremfya (guselkumab) taken?

The standard dosage is:

• 100 mg of guselkumab, administered by subcutaneous injection.

Tremfya (guselkumab) is given at week 0, week 4, and every 8 weeks after that.

It’s meant to be used under a healthcare professional’s guidance. After training, patients can self-inject.

Patients should be tested for tuberculosis (TB) infection before starting Tremfya therapy.

For more details on Tremfya (guselkumab) dosage and administration, see the official prescribing information in our references section.

Note: Please consult with your treating doctor for personalized dosing and potential drug interactions.

Are there any known adverse reactions or side effects of Tremfya (guselkumab)?

Common adverse reactions

The most common side effects (≥1% of patients) listed in the prescribing information include:

• Upper respiratory infections
• Headache
• Injection site reactions
• Arthralgia
• Diarrhea
• Gastroenteritis
• Tinea infections
• Herpes simplex infections

Serious adverse reactions

The serious side effects listed in the prescribing information include:

• Risk of infections: please seek medical help if signs or symptoms of acute or chronic infection occur.

Use in a specific population

Tremfya (guselkumab) can be fatal for a fetus. It is advised to avoid pregnancies and breastfeeding.

Taltz (ixekizumab)